Since only a small percentage of breast cancer cells need to be ER-positive (or PR-positive) for the breast cancer to be hormone-receptor positive, it is not surprising that an earlier sampling of circulating tumor cells yielded ER- negative CTCs. This evidence concerns the gene NR4A1 and breast cancer.